Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema

FHS
March 5, 2024
9:50 am

EXN407 is the first topical SRPK1 inhibitor to demonstrate both safety and signals of biological response as monotherapy for these indications.

Cost becomes a significant factor in smoking cessation efforts

Health concerns are still the primary motive for more than half of those who say they want to stop smoking in England, but cost is

April 23, 2024

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

April 19, 2024

Illinois Cannabis Sales End 2023 Strongly

Illinois adult-use cannabis sales in December were up 10.7% sequentially to a record $153.9 million, which was up by more than the increase in the length of

January 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.